Tumours with ALK fusion mutations are responsive to the tyrosine kinase inhibitor crizotinib however, as with EGFR mutations and TKIs, resistance develops with evidence of secondary ALK point mutations and activation of EGFR signalling in some cases [22]. The gene discussed is ALK; the disease is neoplasm.